Erlotinib (Tarceva(R)) Induced Hair Abnormalities.
- Author:
Chang Min CHOI
1
;
Bark Lynn LEW
;
Woo Young SIM
Author Information
1. Department of Dermatology, College of Medicine, Kyunghee University, Seoul, Korea. bellotte@hanmail.net
- Publication Type:Case Report
- Keywords:
Epidermal growth factor receptor inhibitor;
Erlotinib;
Hair abnormalities
- MeSH:
Adenosine Triphosphate;
Binding, Competitive;
Compliance;
Exanthema;
Female;
Hair;
Humans;
Middle Aged;
Mucositis;
Paronychia;
Polyphosphates;
Protein-Tyrosine Kinases;
Pruritus;
Quinazolines;
Receptor, Epidermal Growth Factor;
Erlotinib Hydrochloride
- From:Korean Journal of Dermatology
2011;49(4):382-384
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor. Patients undergoing anti-EGFR therapy frequently present with cutaneous reactions like a sterile follicular and pustular rash, xerosis, pruritus, paronychia, hair abnormalities and mucositis, which can cause serious discomfort and negatively affect the compliance with anti-EGFR therapy. We report here on an interesting case of hair abnormalities induced by erlotinib (Tarceva(R)) and this presented as eyelash lengthening and hair curling in a 62-year-old woman.
